4BIO Capital — 2024 Investments
4 investments dated 2024 · listed companies and verified rows first · show all
Hornet Therapeutics is a biotech company developing treatments for Epstein-Barr Virus (EBV) driven diseases, with a lead IDO-1 inhibitor (HTX-201) aimed at preventing EBV-implicated conditions such as post-transplantation lymphoproliferative disease.
BiotechMedical Devices
Christoph Hess(Co-founder (Professor))
March Bioscience is a cell therapy company assembling leading scientists and drug developers to advance cell therapy treatments.
BiotechMedical DevicesHouston, US
Sarah Hein(CEO, Co-Founder)inMaksim Mamonkin(Co-Founder, Chair Scientific Advisory Board)Malcolm Brenner(Co-founder)
BoardThomas Luby(Director)inPeter Olagunju(Director)inJoseph Petrosino(Director)
Co-investorsMission BiocapitalCancer FocusCancer FundFitz Gate VenturesKdT VenturesModi Ventures+2 more
Ascend is a gene-to-GMP development partner that helps life-science companies advance advanced therapy products from the research bench through clinical stages.
BiotechHealthtechMedical DevicesMunich, DE
Evis Hursever(Executive Officer)Wesley McConnell(Executive Officer)inMichael Stella(Executive Officer, Director)William Hawkins(Executive Officer)
BoardMichael Beecham(Director)Andrew Kozlov(Director)
Co-investorsCathay HealthDCVC (Data Collective)Monograph Capital PartnersDigitalis Ventures
Hornet is a social networking and chat app for gay men and the broader queer community, offering messaging, a content feed, short videos, and discovery features.
ConsumerImpact & Social GoodMedia & EntertainmentSocial
Christof Wittig(Founder)inDamien BrenierinMitchell Geere
Co-investors500 GlobalMoai CapitalVentech China
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.














